In HER2- Breast Cancer, Brain Mets Are HER2+ 20% of Time In HER2- Breast Cancer, Brain Mets Are HER2+ 20% of Time
Metastases to the brain do not necessarily have the same molecular signature as primary breast tumors. Some are'wolves in sheep's clothing'and are targetable.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 15, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

AI Neither Adds nor Detracts From Chemo in This Setting AI Neither Adds nor Detracts From Chemo in This Setting
The addition of endocrine deprivation therapy to neoadjuvant chemotherapy doesn't increase pathologic complete response rates in hormone receptor-positive, HER2-positive breast cancer, but it doesn't diminish the effectiveness of chemotherapy either, as has long been believed.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 14, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Drug Combo Doubles PFS in Advanced Breast Cancer (CME/CE)
(MedPage Today) -- Everolimus-fulvestrant in metastatic ER-positive, HER2-negative disease (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - December 8, 2016 Category: Geriatrics Source Type: news

No Benefit in Adding AI to Neoadjuvant Treatment for HR+/HER2+ Breast Cancer
The addition of estrogen deprivation to neoadjuvant chemotherapy did not significantly affect pathologic complete response in women with HR-positive, HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 8, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: HER2-Positive Breast Cancer News Conferences/SABCS 2016 Source Type: news

Researchers identify biomarkers of response to treatment in invasive breast cancer
(UNC Lineberger Comprehensive Cancer Center) Researchers report at the San Antonio Breast Cancer Symposium that they have identified biomarkers they believe can be used as part of a larger model to predict how patients with HER2-positive operative breast cancer will respond to the targeted treatment trastuzumab, commercially known as Herceptin, and chemotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 8, 2016 Category: Cancer & Oncology Source Type: news

Adding Everolimus Doubles PFS in AI-Resistant Metastatic Breast Cancer
The addition of everolimus to fulvestrant was associated with more than a doubling of progression-free survival in women with metastatic hormone receptor –positive, HER2-negative breast cancer who were resistant to aromatase inhibitor therapy. (Source: CancerNetwork)
Source: CancerNetwork - December 7, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: News Conferences/SABCS 2016 Source Type: news

A Breast Cancer Drug That Gets In The Brain? Cascadian Sees A Way Forward
Shutterstock Breast cancer patients sometimes end up dying when their tumors spread all the way to the brain. Some very good drugs already exist for patients with breast cancer, especially ones with tumors that overexpress the HER2 marker, but that success has raised a new question: Can drugmakers take another step, [...] (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 7, 2016 Category: Pharmaceuticals Authors: Luke Timmerman, Contributor Tags: NASDAQ:CASC NASDAQ:PBYI Source Type: news

Brain metastasis persists despite improved targeted treatment for HER2 breast cancer
(UNC Lineberger Comprehensive Cancer Center) While new targeted treatments developed across the past two decades have led to dramatic survival improvements for women with HER2-positive metastatic breast cancer, University of North Carolina Lineberger Comprehensive Cancer Center researchers and collaborators report that rates of breast cancer brain metastasis for women with this disease have not substantially declined. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 7, 2016 Category: Cancer & Oncology Source Type: news

Trastuzumab Biosimilar Yields Similar Response Rates in HER2-Positive Breast Cancer
A biosimilar yielded equivalent response rates to trastuzumab at 24 weeks in a study of women with HER2-positive metastatic breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 6, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news

ACE Inhibitors, Beta-Blockers Could Mediate Trastuzumab Cardiac Toxicity
In patients with HER2-positive breast cancer undergoing trastuzumab therapy, the use of an ACE inhibitor or beta-blocker could protect against cardiac toxicity. (Source: CancerNetwork)
Source: CancerNetwork - December 1, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer Cancer Complications HER2-Positive Breast Cancer News Source Type: news

Palbociclib/Letrozole Significantly Delayed Progression in Advanced Breast Cancer
Patients with ER-positive, HER2-negative advanced breast cancer had significant delays in progression when palbociclib was added to letrozole treatment, according to the double-blind PALOMA-2 study. (Source: CancerNetwork)
Source: CancerNetwork - November 17, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Breast Cancer News Source Type: news

NHS to offer first new breast cancer drug for a decade
An estimated 1,380 women a year in England and Wales will benefit from the drug, which is given to patients with the HER2-positive form of breast cancer as soon as they are diagnosed. (Source: the Mail online | Health)
Source: the Mail online | Health - November 17, 2016 Category: Consumer Health News Source Type: news

Drug combination therapy for estrogen-receptor –positive breast cancer passes critical step for worldwide approval
Building on earlier clinical trials, UCLA researchers have confirmed that the “breakthrough” drug palbociclib when used in combination with the traditional hormonal therapy letrozole delays progression of advanced breast cancer significantly and without the harsh side effects seen in some women prescribed letrozole alone.The study, published online today in  the New England Journal of Medicine, is the phase 3 study following phase 1 and phase 2 clinical trials that led toU.S. Food and Drug Administration approval of palbociclib in early 2015. Palbociclib was also approved in Europe for the first time ...
Source: UCLA Newsroom: Health Sciences - November 16, 2016 Category: Universities & Medical Training Source Type: news

New Guidelines for HER2 Testing in Advanced Gastric Cancer New Guidelines for HER2 Testing in Advanced Gastric Cancer
Three professional organizations have jointly released comprehensive, evidence-based guidelines for HER2 testing in advanced gastric cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 15, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FCGR3A Polymorphisms Predict Trastuzumab Benefit in HER2-Positive Breast Cancer
Polymorphisms in the FCGR3A gene are correlated with degree of benefit from trastuzumab in women with ERBB2/HER2-positive breast cancer, according to a new analysis. (Source: CancerNetwork)
Source: CancerNetwork - November 14, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news

IBRANCE(R) (palbociclib) Receives Approval in European Union for the Treatment of Women with HR+/HER2- Metastatic Breast Cancer
NEW YORK--(Healthcare Sales & Marketing Network)--Pfizer Inc. (PFE) today announced that the European Commission (EC) has approved IBRANCE® (palbociclib) for the treatment of women with hormone receptor-positive, human epidermal growth factor receptor ... Biopharmaceuticals, Oncology, Regulatory Pfizer, IBRANCE, palbociclib, HR+/HER2, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 10, 2016 Category: Pharmaceuticals Source Type: news

T-DM1 Offers Similar PFS, More Tolerable in Advanced HER2-Positive Breast Cancer
The antibody-drug conjugate trastuzumab emtansine (T-DM1) showed non-inferior —but not superior—efficacy to trastuzumab plus a taxane in women with advanced HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - November 9, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news

Elevated Troponin Tied to Increased Risk of Trastuzumab-Related Cardiac Dysfunction Elevated Troponin Tied to Increased Risk of Trastuzumab-Related Cardiac Dysfunction
Elevated baseline levels of troponin I and T are associated with an increased risk of trastuzumab-related cardiac dysfunction (TRCD) in women being treated for early-stage HER2-positive breast cancer, researchers report.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - November 4, 2016 Category: Intensive Care Tags: Pharmacist News Source Type: news

Novartis LEE011 receives FDA Priority Review for first-line treatment of HR+ / HER2- advanced breast cancer
The US Food and Drug Administration (FDA) has accepted Novartis' New Drug Application (NDA) for filing and granted Priority Review for LEE011 (ribociclib) as first-line treatment of postmenopausal women with hormone-receptor positive, human-epidermal … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - November 2, 2016 Category: Pharmaceuticals Source Type: news

The Conundrum of Genetic & quot;Drivers & quot; in Benign Conditions The Conundrum of Genetic & quot;Drivers & quot; in Benign Conditions
Genetic alterations such as HER2 and BRAF can be found in benign conditions. Are tumor suppressors preventing such driver mutations from promoting tumorigenesis?Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 1, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Novartis's LEE011 gets FDA fast track in advanced breast cancer
ZURICH (Reuters) - The U.S. Food and Drug Administration has granted priority review status for Novartis drug LEE011 (ribociclib) as a first-line treatment of postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in combination with letrozole, the Swiss drugmaker said on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - November 1, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

HER2 Flip Flop: OncoTherapy Network & Cancer Network
(MedPage Today) -- Also, higher BMI linked to better metastatic RCC survival (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 28, 2016 Category: Hematology Source Type: news

Breast Cancer CTCs Can Flip Between HER2 Negativity and Positivity
Breast cancer tumors that are HER2-negative can spontaneously flip, with populations of circulating HER2-positive cells, suggesting treatment strategy. (Source: CancerNetwork)
Source: CancerNetwork - September 20, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news

Puma Biotechnology Announces FDA Acceptance of NDA for PB272 (Neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
LOS ANGELES, Calif., Sept. 20, 2016 - Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for its lead product... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - September 20, 2016 Category: Drugs & Pharmacology Source Type: news

Updated FISH Guidelines Increase Eligible HER2-Positive Breast Cancer Patients
Using updated FISH guidelines yields more women with breast cancer who may be eligible for HER2-directed therapy. (Source: CancerNetwork)
Source: CancerNetwork - August 27, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer News Source Type: news

EMA accepts Mylan ’s MAA for proposed biosimilar trastuzumab for review
The European Medicines Agency (EMA) has accepted for review Mylan's marketing authorisation application (MAA) for a proposed biosimilar Trastuzumab, MYL-1401O, to treat certain human epidermal growth factor receptor 2 (HER2)-positive breast and gastr … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 25, 2016 Category: Pharmaceuticals Source Type: news

New standard helps ensure accurate clinical measurements of HER2 breast cancer gene
Study demonstrates value of new measurement reference for both evaluating assay performance and increasing confidence in reporting HER2 amplification for clinical applications. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 17, 2016 Category: Science Source Type: news

New standard helps ensure accurate clinical measurements of HER2 breast cancer gene
(National Institute of Standards and Technology (NIST)) Study demonstrates value of new measurement reference for both evaluating assay performance and increasing confidence in reporting HER2 amplification for clinical applications. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 17, 2016 Category: Biology Source Type: news

Novartis CDK4/6 Inhibitor LEE011 (Ribociclib) Receives FDA Breakthrough Therapy Designation as First-Line Treatment for HR+/HER2- Advanced Breast Cancer
EAST HANOVER, N.J., Aug. 3, 2016 -- (Healthcare Sales & Marketing Network) -- Novartis announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to LEE011 (ribociclib), in combination with letrozole, for t... Biopharmaceuticals, Oncology, FDA Novartis, ribociclib, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 3, 2016 Category: Pharmaceuticals Source Type: news

Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer
Novartis announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to LEE011 (ribociclib), in combination with letrozole, for the treatment of hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. (Source: World Pharma News)
Source: World Pharma News - August 3, 2016 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Updated testing guidelines make more women eligible for herceptin, yet benefit uncertain
Changes to HER2 testing guidelines for breast cancer in 2013 significantly increased the number of patients who test HER2-positive, according to a new study. Cancers that have an excess of HER2 protein or extra copies of the HER2 gene are called HER2-positive and can be treated with drugs like Herceptin that target HER2. HER2 stands for human epidermal growth factor receptor 2. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 27, 2016 Category: Science Source Type: news

Updated testing guidelines make more women eligible for herceptin, yet benefit uncertain
( Mayo Clinic ) Changes to HER2 testing guidelines for breast cancer in 2013 significantly increased the number of patients who test HER2-positive, according to a new study by Mayo Clinic researchers published in the Journal of Clinical Oncology. Cancers that have an excess of HER2 protein or extra copies of the HER2 gene are called HER2-positive and can be treated with drugs like Herceptin that target HER2. HER2 stands for human epidermal growth factor receptor 2. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 27, 2016 Category: Cancer & Oncology Source Type: news

Updated Testing Guidelines Make More Women Eligible for Herceptin, yet Benefit Uncertain
ROCHESTER, Minn. — Changes to HER2 testing guidelines for breast cancer in 2013 significantly increased the number of patients who test HER2-positive, according to a new study by Mayo Clinic researchers published in the Journal of Clinical Oncology. Cancers that have an excess of HER2 protein or extra copies of th e HER2 gene are called [...] (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - July 27, 2016 Category: Research Source Type: news

Puma reports interim Phase III ExteNET trial results of PB272 to treat HER2-positive breast cancer
US-based biopharmaceutical company Puma Biotechnology has reported interim 5-year disease free survival data from the Phase III ExteNET trial of PB272 (neratinib) for an adjuvant treatment of early stage, HER2-positive breast cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - July 26, 2016 Category: Pharmaceuticals Source Type: news

Amgen And Allergan Announce Top-Line Results From Phase 3 Study Evaluating ABP 980 Compared With Trastuzumab In Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer
THOUSAND OAKS, Calif. and DUBLIN, July 21, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced results from a Phase 3 study evaluating efficacy and safety of ABP 980 compared with trastuzumab in patients with human epidermal growth factor receptor 2-positive (HER2-positive) early breast cancer. The results ruled out inferiority compared to trastuzumab but could not rule out superiority based on its primary efficacy endpoint of the difference of the percentage of patients with a pathologic complete response (pCR). The primary endpoint had a prespecified equivalence margin of +/- 13 perc...
Source: Amgen News Release - July 21, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Puma Biotechnology Submits New Drug Application for PB272 (Neratinib) to FDA for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
LOS ANGELES, Calif., July 21, 2016 - Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candidate PB272 (neratinib) for... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - July 21, 2016 Category: Drugs & Pharmacology Source Type: news

Boehringer Ingelheim and Lilly announce clinical trial collaboration in metastatic breast cancer
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced a new collaboration on a Phase 1b study that will evaluate the safety and tolerability of BI 836845, Boehringer Ingelheim's insulin-like growth factor (IGF)-1/IGF-2 ligand neutralising antibody, in combination with abemaciclib (LY2835219), Lilly’s cyclin-dependent kinase (CDK) 4 and 6 inhibitor, in patients diagnosed with HR+/HER2- mBC. (Source: World Pharma News)
Source: World Pharma News - July 13, 2016 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

Emerging Therapies for Metastatic Breast CancerEmerging Therapies for Metastatic Breast Cancer
Therapeutic options are set to increase for patients with refractory HR-positive or HER2-positive metastatic breast cancer, as evidenced by presentations at ASCO 2016. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 22, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology Article Source Type: news

Can Anthracyclines Be Withheld in High-Risk HER2- Breast Cancer?Can Anthracyclines Be Withheld in High-Risk HER2- Breast Cancer?
At ASCO 2016, the results of the ABC suite of trials provided guidance on a very important clinical question in breast cancer management. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 6, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Cheaper Breast Cancer Drug Does Well in Clinical Trial
It has similar effectiveness, safety compared to Herceptin for HER2-positive disease (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 4, 2016 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Family Medicine, Nursing, Oncology, Pharmacy, Research, News, Source Type: news

Cheaper Breast Cancer Drug Shows Promise
It has similar effectiveness, safety compared to Herceptin for HER2-positive disease (Source: WebMD Health)
Source: WebMD Health - June 3, 2016 Category: Consumer Health News Source Type: news

Cheaper Breast Cancer Drug Does Well in Clinical Trial
FRIDAY, June 3, 2016 -- For women with advanced HER2-positive breast cancer, a similar but less expensive experimental drug works just as well as the standard drug Herceptin (trastuzumab), a new study finds. HER2-positive tumors contain certain... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 3, 2016 Category: Journals (General) Source Type: news

Promising treatment prospects for invasive breast cancer
In Switzerland alone, more than 5,700 women are diagnosed with breast cancer each year, and almost 1,400 of those affected die of the disease. In many very invasive forms of breast cancer, the cells have too much of the receptor HER2 on their surface. This leads to uncontrolled growth of the cells. (Source: World Pharma News)
Source: World Pharma News - June 3, 2016 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Cheaper Breast Cancer Drug Does Well in Clinical Trial
It has similar effectiveness, safety compared to Herceptin for HER2-positive disease (Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - June 3, 2016 Category: Cancer & Oncology Source Type: news

Breast Cancer: Big Questions Answered?Breast Cancer: Big Questions Answered?
Dr Kathy Miller previews the top ASCO 2016 breast cancer studies, which may provide definitive answers about anthracyclines in HER2-negative BC and optimal duration for adjuvant aromatase inhibitors. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 24, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

HER2+ Colorectal Cancer: Slicing the Pie Into Curable PortionsHER2+ Colorectal Cancer: Slicing the Pie Into Curable Portions
Dr John Marshall views a study of dual targeting in HER2+ CRC as an argument for combining broad molecular testing and precision medicine to slice the cancer pie into curable portions. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 23, 2016 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

HER2 Therapy in Advanced Colorectal Cancer: 'Extraordinary'HER2 Therapy in Advanced Colorectal Cancer: 'Extraordinary'
Treatment-refractory HER2-positive metastatic colorectal cancer patients achieve remarkable response to a combination targeted therapy regimen. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 3, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New Neoadjuvant Combination for HER+ Breast CancerNew Neoadjuvant Combination for HER+ Breast Cancer
A presurgery combination of trastuzumab emtansine and pertuzumab was significantly better than the standard of care, paclitaxel and trastuzumab, for HER2+ invasive breast cancer. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 25, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

'Disturbing' Disparity in Use of Key Breast Cancer Drug'Disturbing' Disparity in Use of Key Breast Cancer Drug
A study indicates that black patients with HER2+ breast cancer are 25% less likely to receive trastuzumab than are white patients--an underuse that may affect outcomes, reports Dr Lidia Schapira. Medscape Oncology (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - April 25, 2016 Category: Internal Medicine Tags: Hematology-Oncology Viewpoint Source Type: news

New ASCO Guide for Adjuvant Therapy in Early Breast CancerNew ASCO Guide for Adjuvant Therapy in Early Breast Cancer
ASCO has issued its first comprehensive clinical guidelines on adjuvant chemotherapy in early breast cancer and targeted adjuvant therapy for HER2-positive disease. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 23, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news